Salarius Pharmaceuticals, Inc. (SLRX) Financial Ratios
10 years of historical data (2015–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
0.03
↓-98% vs avg
5yr avg: 1.62
30Y Low0.5·High15.2
ROE
↓
-164.0%
↑-52% vs avg
5yr avg: -107.9%
30Y Low-164%·High-32%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
SLRX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Salarius Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $697790 | $2M | $17M | $26M | $21M | $14M | $12M | $29.9B | $302.7B | $430.7B | $1.4B |
| Enterprise Value | $-1514872 | $-433345 | $11M | $14M | $-8610306 | $4M | $9M | $29.9B | $302.7B | $430.7B | $1.3B |
| P/E Ratio → | -0.01 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | 2.72 | 3.58 | 35646.01 | 237508.17 | 426175.78 | — |
| P/B Ratio | 0.03 | 1.18 | 3.23 | 2.52 | 0.53 | 0.64 | 1.17 | 3218.49 | 10400.09 | 7261.28 | 15.24 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
SLRX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | 0.69 | 2.65 | 35634.28 | 237493.12 | 426153.60 | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
SLRX Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -164.0% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | 100.0% | 100.0% | 48.6% | 60.3% | 34.4% | — |
| Operating Margin | — | — | — | — | — | -148.8% | -238.5% | -2633.7% | -2724.6% | -3946.5% | — |
| Net Profit Margin | — | — | — | — | — | -140.5% | -200.2% | -2615.6% | -2701.7% | -3907.6% | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -164.0% | -164.0% | -160.1% | -128.7% | -41.9% | -44.9% | -69.8% | -114.2% | -77.9% | -52.1% | -31.6% |
| ROA | -116.0% | -116.0% | -118.1% | -113.9% | -38.8% | -37.9% | -57.1% | -96.6% | -70.1% | -49.9% | -30.7% |
| ROIC | — | — | — | -613.4% | -91.4% | -61.9% | -182.4% | -353.3% | -111.2% | -95.9% | -85.9% |
| ROCE | -168.7% | -168.7% | -164.6% | -129.7% | -42.1% | -47.6% | -103.6% | -127.9% | -78.5% | -52.6% | -31.7% |
SLRX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $2M exceeds total debt of $221866, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.15 | 0.15 | 0.05 | — | — | 0.02 | 0.05 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.46 | -1.06 | -1.17 | -0.75 | -0.48 | -0.31 | -1.06 | -0.66 | -0.38 | -0.72 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | -2555.41 | — | — | — | — | — |
Net cash position: cash ($2M) exceeds total debt ($221866)
SLRX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.98x means Salarius Pharmaceuticals, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 3.40x to 1.98x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.98 | 1.98 | 5.02 | 3.40 | 14.29 | 5.70 | 1.42 | 2.06 | 5.91 | 16.06 | 32.40 |
| Quick Ratio | 1.98 | 1.98 | 5.02 | 3.40 | 14.29 | 5.70 | 1.42 | 2.02 | 5.83 | 15.94 | 32.40 |
| Cash Ratio | 1.61 | 1.61 | 4.54 | 2.84 | 13.84 | 4.01 | 1.13 | 1.96 | 5.70 | 15.70 | 32.08 |
| Asset Turnover | — | — | — | — | — | 0.21 | 0.25 | 0.08 | 0.04 | 0.02 | — |
| Inventory Turnover | 2.30 | — | — | — | — | — | — | 2.30 | 1.17 | 1.46 | — |
| Days Sales Outstanding | — | — | — | — | — | 268.94 | — | 4.33 | 2.97 | 4.40 | — |
SLRX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Salarius Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | 1.1% | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.1% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $64468 | $218730 | $142342 | $13858 | $5219 | $1095 | $1M | $1M | $1M | $1504 |
Peer Comparison
Compare SLRX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 SLRXYou | $697790 | -0.0 | — | — | — | — | -164.0% | — | — |
 IMVT | $6B | -10.5 | — | — | — | — | -62.5% | — | — |
 KROS | $438M | 5.1 | 2.3 | 4.1 | 99.4% | 28.9% | 19.9% | 167.9% | 0.2 |
 TPVG | $226M | 4.6 | 8.9 | — | 83.5% | 77.9% | 14.1% | 7.2% | 6.2 |
 AGEN | $137M | -1144.1 | — | — | 90.3% | -18.0% | — | — | — |
 ALDX | $105M | -1.9 | — | — | — | — | -58.5% | -369.4% | — |
 RVMD | $32B | -25.4 | — | — | — | — | -58.1% | -54.3% | — |
 AUPH | $2B | 7.8 | 20.4 | 15.9 | 88.5% | 37.1% | 59.9% | 16.6% | 0.7 |
 SYRS | $10733 | -0.0 | — | — | 77.3% | -1298.2% | -227.9% | — | — |
 MGNX | $191M | -2.6 | — | — | — | -48.7% | -86.9% | -1879.3% | — |
 CRL | $9B | -62.5 | 13.0 | 17.3 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 10 years · Updated daily
See SLRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SLRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SLRX vs IMVT
Side-by-side business, growth, and profitability comparison vs Immunovant, Inc..
Start ComparisonSLRX — Frequently Asked Questions
Quick answers to the most common questions about buying SLRX stock.
What is Salarius Pharmaceuticals, Inc.'s P/E ratio?
Salarius Pharmaceuticals, Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
What is Salarius Pharmaceuticals, Inc.'s ROE?
Salarius Pharmaceuticals, Inc.'s return on equity (ROE) is -164.0%. The historical average is -88.5%.
Is SLRX stock overvalued?
Based on historical data, Salarius Pharmaceuticals, Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.